STARTING YOUR PATIENTS ON KESIMPTA

Life with RMS is complicated, starting treatment shouldn't be

Getting patients started on KESIMPTA

SCREEN

Bloodwork to screen patients
for
HBV and test their Ig levels1

Kesimpta sensoready pen icon.

SHOW

Demonstrate KESIMPTA administration
using the Sensoready® Demo Pen

Kesimpta start form icon.

START

Start today with samples.*
Submit 1-page Start Form

We'll automatically enroll your patient in Alongside™ KESIMPTA for support and assistance throughout their first year on treatment.

  • HBV and Ig testing can be added to your patient's regular blood panels

  • Training pens and videos are provided by Novartis. We can also provide supplemental one-on-one training for your patient virtually or at home

  • Before initiating KESIMPTA, discuss treatment, including possible side effects like injection reactions, and explain to patients that they start with 1 dose a week for the first 3 weeks, then skip the 4th week before starting once-monthly maintenance dosing

  • Patients can visit KESIMPTA.com for more details, and may also self-enroll in our Alongside program from the patient site

*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.

Back to top

Patient resources

Novartis is committed to providing patients with access to medication regardless of their ability to pay. Below you'll find the materials and forms you may need to help your patients get started on KESIMPTA.

For your patients

Resources to help your patients with RMS prepare to use KESIMPTA

Download Considering
KESIMPTA Brochure
Download Quick Tips
for Use Brochure
Back to top

Personalized support for your patients to start and stay on track with treatment

  • Dedicated Alongside KESIMPTA Coordinators tailor support so patients are prepared, not overwhelmed

  • See what else we can help with on the Alongside KESIMPTA page

Patient injection training

See how patients learn to use the Sensoready Pen

See patient-friendly live action tips for injection with the pen

Ensure that your patients are getting the coverage and support they need.

Call 1-855-537-46781-855-537-4678 for assistance or questions about how to enroll your patients in Alongside KESIMPTA. Support is available 8:30 AM to 8:00 PM ET, Mon-Fri.
Back to top
'It was great that I could get started on Kesimpta right away.' - Kristin: mother, real estate agent, Kesimpta patient.

It was great that I could get started on
KESIMPTA right away.

Kristin: mom, real estate agent, KESIMPTA patient†

†Actual KESIMPTA patient who was compensated for their time. Individual results may vary.

Support for your practice

Everything you need to start patients quickly

Start today with samples

KESIMPTA offers a free trial through
its sample program to get patients
started today*

Contact a rep for more info

5 days to bridge product

80% of commercial patients
receive their first bridge dose in
5 days2

Based on prescription and dispense data as of
November 2022.

92% coverage

The vast majority of commercial
lives covered on KESIMPTA3†

Download the KESIMPTA Start Form

Download the KESIMPTA
Start Form

DOWNLOAD ENGLISH DOWNLOAD SPANISH

*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.

†Based on unrestricted or single-step edit coverage. Example based on prescription data as of September 2021.

Back to top

Resources to help make KESIMPTA part of your practice

See our educational videos
about
KESIMPTA and the
Sensoready Pen

Visit the KESIMPTA Video Library

GO TO LIBRARY
Back to top

Templates to help navigate insurance coverage

Visit patient site

Information and resources for treatment with KESIMPTA are available directly to patients. View the KESIMPTA patient site and learn more about these helpful patient services.

VISIT PATIENT SITE
'I can help people with anything they need to get started on Kesimpta, from assisting with insurance questions to training on the Sensoready Pen.' - Leticia, Alongside Coordinator.

I can help people get started on KESIMPTA, from
assisting with insurance questions to providing
supplemental training on the Sensoready Pen.

Leticia, Alongside Coordinator

Learn about our patient support
program

Start patients on KESIMPTA today

DOWNLOAD START FORM

Submit a Start Form by fax or online at CoverMyMeds®

VISIT COVERMYMEDS®
Back to top

HBV=hepatitis B virus; Ig=immunoglobulin; MOA=mechanism of action; RMS=relapsing multiple sclerosis.

References: 1. Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2022. 3. Data on file. Market access. Novartis Pharmaceuticals Corp; East Hanover, NJ. September 2021.

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

SEE IMPORTANT SAFETY INFORMATION

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections including serious bacterial, fungal, and new or reactivated viral infections; some have been fatal in patients treated with other anti-CD20 antibodies. The overall rate of infections and serious infections in KESIMPTA-treated patients was similar to teriflunomide-treated patients (51.6% vs 52.7%, and 2.5% vs 1.8%, respectively). The most common infections reported by KESIMPTA-treated patients in relapsing MS (RMS) trials included upper respiratory tract infection (39%) and urinary tract infection (10%). Delay KESIMPTA administration in patients with an active infection until resolved.

Consider the potential increased immunosuppressive effects when initiating KESIMPTA after an immunosuppressive therapy or initiating an immunosuppressive therapy after KESIMPTA.

Hepatitis B Virus: Reactivation: No reports of hepatitis B virus (HBV) reactivation in patients with MS treated with KESIMPTA. However, HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with ofatumumab at higher intravenous doses for chronic lymphocytic leukemia (CLL) than the recommended dose in MS and in patients treated with other anti-CD20 antibodies.

Infection: KESIMPTA is contraindicated in patients with active hepatitis B disease. Fatal infections caused by HBV in patients who have not been previously infected have occurred in patients treated with ofatumumab at higher intravenous doses for CLL than the recommended dose in MS. Perform HBV screening in all patients before initiation of KESIMPTA. Patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], should consult liver disease experts before starting and during KESIMPTA treatment.

Progressive Multifocal Leukoencephalopathy: No cases of progressive multifocal leukoencephalopathy (PML) have been reported for KESIMPTA in RMS clinical studies; however, PML resulting in death has occurred in patients being treated with ofatumumab at higher intravenous doses for CLL than the recommended dose in MS. In addition, JC virus infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies. If PML is suspected, withhold KESIMPTA and perform an appropriate diagnostic evaluation. If PML is confirmed, KESIMPTA should be discontinued.

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to starting KESIMPTA for inactivated vaccines. The safety of immunization with live or live-attenuated vaccines following KESIMPTA therapy has not been studied. Vaccination with live or live-attenuated vaccines is not recommended during treatment and after discontinuation until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with KESIMPTA During Pregnancy. For infants whose mother was treated with KESIMPTA during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines. If the B-cell count has not recovered in the infant, do not administer the vaccine as having depleted B-cells may pose an increased risk in these infants.

Injection-Related Reactions: Injection-related reactions with systemic symptoms occurred most commonly within 24 hours of the first injection, but were also observed with later injections. There were no life-threatening injection reactions in RMS clinical studies.

The first injection of KESIMPTA should be performed under the guidance of an appropriately trained health care professional. If injection-related reactions occur, symptomatic treatment is recommended.

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections and after discontinuation of therapy until B-cell repletion. Consider discontinuing KESIMPTA therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Fetal Risk: Based on animal data, KESIMPTA can cause fetal harm due to B-cell lymphopenia and reduce antibody response in offspring exposed to KESIMPTA in utero. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception while receiving KESIMPTA and for at least 6 months after the last dose.

Most common adverse reactions (>10%) are upper respiratory tract infection, headache, injection-related reactions, and local injection-site reactions.

Please see full Prescribing Information, including Medication Guide.

KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.

ALONGSIDE is a trademark of Novartis AG.

CoverMyMeds is a registered trademark of CoverMyMeds, LLC.

All registered trademarks are the property of their respective owners.